RU486
article
OA: closed
CC0
⤵ 16 in-corpus citations
Abstract
More than a decade after the serendipidous discovery of RU486, numerous antiprogestins have been synthesized and studied. Interest in how antiprogestins exert their antagonist effect has led to novel information about the molecular mechanisms of progesterone action. The pivotal role that progesterone plays in reproductive biology has led to research in many areas where a potential role for these compounds may be found in health and disease. RU486 has been shown to relieve pelvic pain associated with endometriosis and to decrease American Fertility Society endometriosis scores. Uterine leiomyomata show a significant reduction in size after administration of RU486 for 3 months. Although much research remains to be carried out, RU486 appears promising as alternative therapies for these diseases.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
Cited by (16)
- Mifepristone 2.5, 5, 10mg versus placebo in the treatment of endometriosis 2015
- Antiprogestins in gynecological diseases 2014
- Screening of a panel of steroid-related genes showed polymorphisms of aromatase genes confer susceptibility to advanced stage endometriosis in the Taiwanese Han population 2013
- Progesterone Action in Endometrial Cancer, Endometriosis, Uterine Fibroids, and Breast Cancer 2013
- Endometriosis 2009
- Chapter 2 Progesterone Receptor Action in Leiomyoma and Endometrial Cancer 2009
- Endometriosis 2008
- Progesterone receptor antagonists and selective progesterone receptor modulators: proven and potential clinical applications 2007
- Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications 2005
- The effects of 1-month administration of asoprisnil (J867), a selective progesterone receptor modulator, in healthy premenopausal women 2005
- Progesterone antagonists and progesterone receptor modulators: an overview 2003
- Progesterone receptor modulators and progesterone antagonists in women's health 2000
- Mechanism of action and clinical effects of antiprogestins on the non-pregnant uterus 1998
- EXTRAPELVIC ENDOMETRIOSIS 1997
- Etiology and Management of Chronic Pelvic Pain Syndromes 1997
- Antiprogestins: Mechanism of Action and Contraceptive 1996
Source provenance
- europepmc
- last seen: 2026-06-11T06:19:48.454388+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-05-13T22:11:24.284338+00:00
License: CC0
· commercial use OK